Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Thromboembolism is the most common cause of death in autopsied patients. Recently, this disorder has become a topic of interest due to it being a frequent complication of COVID-19 infection. This book discusses pulmonary thromboembolism in COVID-19 and non-COVID-19 patients, such as those with malignancies such as paraneoplastic symptoms or heart and lung diseases.

Pulmonary embolism. --- Thromboembolism.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Thromboembolism is a compelling challenge in cancer care because of its life-threatening nature as well as its impact on specific treatments. Current guidelines do not generally recommend antithrombotic prophylaxis, except in selected categories of patients at high risk of thrombosis. Accordingly, several clinical decision models have been developed to guide the oncologist in thromboembolic risk assessment and targeted prophylaxis. Low-molecular-weight heparins (LMWH) are currently considered as the standard approach in clinical practice guidelines, but recent randomized controlled trials (RCT) indicate that direct oral anticoagulants (DOACs) are effective for the treatment/prophylaxis of cancer-associated thromboembolism. However, many unanswered questions remain on the efficacy and safety of anticoagulants in selected cancer subgroups, and in primary and secondary prevention settings, where anticoagulation needs to be balanced on the risk of bleeding complications. Presently, patient selection remains the main challenge. Improvement in existing VTE risk models or the construction of alternative risk assessment tools are needed in order to ameliorate the risk stratification of cancer patients. This reprint will cover the current clinical evidence supporting the standard of care and emerging treatment/prophylactic options for cancer-associated thromboembolism during both active treatment and simultaneous/palliative care. Tailored approaches based on the use of individualized factors to stratify the thrombotic/bleeding risk in each individual patient are discussed.

multiple myeloma --- venous thromboembolism --- risk assessment models --- thromboprophylaxis --- direct oral anticoagulants --- cancer-associated venous thromboembolism --- thrombosis --- pulmonary embolism --- neoplasms --- anticoagulants --- coumarins --- low molecular weight heparins --- cancer --- endogenous heparin --- heparanase --- heparan sulfate --- hospice --- palliative care units --- low molecular weight heparin --- deep vein thrombosis --- cancer associated thrombosis --- VTE --- malignancy --- direct oral anticoagulant --- pancreatic cancer --- low-molecular weight heparin --- survival --- coagulation activation --- locally advanced breast cancer --- prognostic model --- pCR --- treatment --- prophylaxis --- DOAC --- simultaneous care --- integrated care --- lymphoma --- Non-Hodgkin lymphoma --- Hodgkin lymphoma --- risk factors --- molecular subtype --- arterial thrombosis --- ALK --- ROS1 --- KRAS --- chemotherapy --- low-molecular-weight heparin (LMWH) --- VKA --- UFH --- DOACs --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Perioperative care practices worldwide are in the midst of a seeing change with the implementation of multidisciplinary processes that improve surgical outcomes through (1) better patient education, engagement, and participation; (2) enhanced pre-operative, intra-operative, and post-operative care bundles; and (3) interactive audit programs that provide feedback to the surgical team. These improved outcomes include reductions in the frequency and severity of complications and improved throughput, which ultimately reduce operative stress. Practices in theatre as well as ward are becoming more collaborative and evidence-driven.This book is best utilized by perioperative care team members engaged in quality improvement, collaborative practice, and application of innovations in surgical care.

colorectal surgery --- pediatric --- surgical prophylaxis --- antibiotic prophylaxis --- surgical site infections --- collaboration --- enhanced recovery --- infection, surgical wound --- perioperative care --- pharmacy, clinical --- post-operative nausea and vomiting --- prophylaxis --- surgeon --- surgery --- colorectal --- gynecological --- thromboembolism --- venous --- anesthesiology --- COVID-19 --- nursing --- pediatrics --- pharmacy --- surgical home --- perioperative --- team-based care --- malignant hyperthermia --- collaborative practice --- heart transplant --- tricuspid annuloplasty --- tricuspid regurgitation --- prophylactic --- meta-analysis --- pain management --- opioid stewardship --- postoperative pain --- multimodal analgesia --- regional anesthesia --- preemptive analgesia --- perioperative medication management --- transitions of care --- opioid-related adverse effects --- wearable biosensors --- critical care --- vital sign monitoring --- bio-monitoring system --- technology acceptance --- integration --- implementation --- surgical care --- quality improvement --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Plants have served mankind as an important source of foods and medicines. While we all consume plants and their products for nutritional support, a majority of the world population also rely on botanical remedies to meet their health needs, either as their own “traditional medicine” or as “complementary and alternative medicine”. From a pharmaceutical point of view, many compounds obtained from plant sources have long been known to possess bio/pharmacological activities, and historically, plants have yielded many important drugs for human use, from morphine discovered in the early nineteenth century to the more recent paclitaxel and artemisinin. Today, we are witnessing a global resurgence in interest and use of plant-based therapies and botanical products, and natural products remain an important and viable source of lead compounds in many drug discovery programs.This Special Issue on “Plant Natural Products for Human Health” compiles a series of scientific reports to demonstrate the medicinal potentials of plant natural products. It covers a range of disease targets, such as diabetes, inflammation, cancer, neurological disease, cardiovascular disease, liver damage, bacterial, and fungus infection and malarial. These papers provide important insights into the current state of research on drug discovery and new techniques. It is hoped that this Special Issue will serve as a timely reference for researchers and scholars who are interested in the discovery of potentially useful molecules from plant sources for health-related applications.

PhGs --- bitter orange --- immunomodulator --- A549 cells --- bergapten --- triptolide --- BMP/Smad --- phytochemicals --- antioxidant enzymes --- kumquat --- MTT assay --- HepaRG cells --- human health --- nanoparticles --- dendritic cells --- drug discovery --- biofilm --- catechin --- antitubercular activity --- Panax notoginseng saponins --- animals --- mouse-hair growth --- A? --- curcumin --- WNT/?-catenin --- copaiba --- AD --- Plasmodium parasites --- traditional medicine --- procyanidin A2 --- PET inhibition --- rheumatoid arthritis --- cannabinoid type 1 receptor --- iridoids --- inflammatory bowel disease --- acute liver injury --- human-hair-follicle dermal papilla cells --- Neuroprotective --- dihydromyricetin --- AMPK --- thromboembolism --- ginseng --- drug design and development --- endoplasmic reticulum stress --- mitogen-activated protein kinase --- Nrf2 --- prenylated flavonoids --- inflammation --- preclinical studies --- plants --- dietary supplements --- Glycyrrhiza uralensis --- aspirin --- Tripterygium wilfordii --- P. eryngii --- reperfusion --- ethnopharmacology --- glucans --- innovation --- hpatoprotection --- hinokitiol --- phytocannabinoid --- antistaphylococcal activity --- Shh/Gli --- green tea --- sesquiterpenoids --- adjuvant-induced arthritis --- yuzu --- hepatotoxicity --- p53/Bax --- Keap1 --- nuclear factor-kappaB --- oxidative stress --- pharmacokinetic study --- cinnamamides --- toxicity --- APAP --- Astragali Radix --- computational softwares --- plant natural product --- onion --- anti-malaria activity --- lipogenesis --- bleeding time --- diterpenoids --- Penthorum chinense Pursh --- myocardial hypertrophy --- automation --- adjuvant --- grapefruit --- melanoma cell --- essential oil --- sweet orange --- Amadori rearrangement compounds --- heme oxygenase --- global health --- calorie restriction --- bergamot --- liposomes --- EGCG --- celastrol --- herb–drug interactions --- cannabigerol --- anti-inflammation --- OH· free radical --- molecular targets --- gluconeogenesis --- microbiome --- SIRT1 --- fucoidan --- heart --- PC12 cells --- acetaminophen --- omics --- time-kill assay --- arthritis --- lychee seed --- bioinformatics --- structure–activity relationship --- precision medicine --- orange petitgrain --- immune modulation --- antiproliferation --- flavonoids --- scoulerine --- oleoresin --- triterpenic acids --- Cannabis sativa --- NAFLD --- biological activity --- differentiation --- oxygen consumption rate --- mitochondrial bioenergetics --- neroli --- apoptosis --- targeted delivery --- platelet activation --- protein kinase --- heat-process --- hepatic steatosis --- hyperglycemia --- natural products --- lemon --- genistein --- neuroinflammation --- astragaloside IV --- cytoxicity --- flavonoid --- paracetamol --- medicinal plants --- insulin resistance --- resveratrol --- mandarin --- garlic --- TGF-? --- morin hydrate --- sirtuin 3 --- MMPs --- gomisin N --- lime --- Ziziphus jujuba --- antifungal activity --- ischemia --- migration --- caspases --- small molecules